Genmab A/S (LON:0MGB)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 14.61B |
| Revenue (ttm) | 2.86B |
| Net Income (ttm) | 1.18B |
| Shares Out | n/a |
| EPS (ttm) | 18.67 |
| PE Ratio | 12.40 |
| Forward PE | 26.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,588 |
| Average Volume | 24,078 |
| Open | 2,188.00 |
| Previous Close | 2,213.70 |
| Day's Range | 2,162.00 - 2,202.00 |
| 52-Week Range | 1,168.50 - 2,256.00 |
| Beta | 0.79 |
| RSI | 61.37 |
| Earnings Date | Feb 17, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit
(RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific antibody, versu...
Genmab (GMAB) Phase 3 Trial Results: Impact and Future Outlook
Genmab (GMAB) Phase 3 Trial Results: Impact and Future Outlook
Genmab's (GMAB) Epcoritamab Shows Promise in DLBCL Trial
Genmab's (GMAB) Epcoritamab Shows Promise in DLBCL Trial
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study
Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody admi...
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-14. The following slide deck was published by Genmab A/S in conjunction with this event.
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Genmab A/S at JPMorgan Healthcare Conference Transcript
Genmab A/S at JPMorgan Healthcare Conference Transcript
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Genmab AS (OCSE:GMAB)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Genmab AS (OCSE:GMAB)
Genmab: AI Partnership And Clinical Data Fuel Growth
Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI R&D. See why GMAB stock is a buy.
Why Are Investors Paying Attention To Genmab Stock?
Shares of Genmab (NASDAQ: GMAB) are rising ... Full story available on Benzinga.com
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
COPENHAGEN, Denmark--(BUSINESS WIRE)-- #AI--Genmab has partnered with Anthropic to advance its research and development (R&D) processes through the adoption of agentic AI capabilities.
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Media Release COPENHAGEN, Denmark; January 5, 2026 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44 th Annual J.P. Morgan Hea...
Genmab (GMAB) Ends Acasunlimab Development, Analysts Support Move
Genmab (GMAB) Ends Acasunlimab Development, Analysts Support Move
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab. The decision was made as part of Genmab’s strategic focus on the most value‑creating opportun...
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab.
Genmab (GMAB) Shifts Focus, Discontinues Acasunlimab Development
Genmab (GMAB) Shifts Focus, Discontinues Acasunlimab Development
Genmab ends development of late-stage oncology asset acasunlimab
Genmab shifts focus to Epkinly and pipeline, discontinuing development of acasunlimab. Read more here.
Genmab (GMAB) Shifts Focus from Acasunlimab to High-Potential Programs
Genmab (GMAB) Shifts Focus from Acasunlimab to High-Potential Programs
Genmab scraps development of experimental cancer therapy
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.
Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs
(RTTNews) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as EPKINLY, petosem...
Genmab (GMAB) Ends Development of Acasunlimab to Focus on Promising Projects
Genmab (GMAB) Ends Development of Acasunlimab to Focus on Promising Projects
Genmab Portfolio Prioritization Update
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strateg...